1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
Recruiting
Phase 1Interventional Study
Hidradenitis Suppurativa (HS)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 60
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
30 (estimated)
Sponsor
Wynn Medical Center · Other
Who this trial is looking for
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin. HS begins around the hair follicle; when the follicle becomes blocked and inflamed, new lesions form. Prior clinical studies of lasers that act on the hair follicle have shown improvement in HS symptoms, and a 1726-nm diode laser-designed to selec…
Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin. HS begins around the hair follicle; when the follicle becomes blocked and inflamed, new lesions form. Prior clinical studies of lasers that act on the hair follicle have shown improvement in HS symptoms, and a 1726-nm diode laser-designed to selectively heat oil glands within the follicle-has reduced inflammatory lesions in acne with good tolerability across many skin types.
This study will test whether a 1726-nm diode laser can safely reduce inflammatory HS lesions in Hurley stage I-II disease. Adults with bilateral (right/left) affected areas will be randomized so that one side receives active laser treatment and the other side receives a sham procedure. Participants will have three treatment sessions over 8 weeks and follow-up through Week 24 while continuing their stable HS medications.
The primary outcome is the percent change in abscess and inflammatory nodule counts on the treated side versus the sham side at Week 16. Secondary outcomes include validated HS responder scores, pain, quality of life, flare rate/antibiotic use, and safety. Results may support a non-ablative, follicle-directed option for early HS.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Adults 18-60 years; any sex; Fitzpatrick I-VI.
* Clinical HS, Hurley I-II (Investigator confirmed).
* At least one inflammatory nodule in a paired, bilateral region (axilla, groin/inguinal, inframammary, inner thigh, or buttock) within 4 weeks prior to baseline.
* Able to read…
Inclusion Criteria:
* Adults 18-60 years; any sex; Fitzpatrick I-VI.
* Clinical HS, Hurley I-II (Investigator confirmed).
* At least one inflammatory nodule in a paired, bilateral region (axilla, groin/inguinal, inframammary, inner thigh, or buttock) within 4 weeks prior to baseline.
* Able to read/speak English/Chinese/Spanish/Vietnamese and sign consent.
* Willing/able to comply with visits, pre/post-care, standardized photography.
* Agree to avoid new HS procedures/therapies in study areas through Week 24.
* No laser contraindication; agrees to shave/clip hair before treatments.
* Optional translational cohort: willing to undergo 4-mm punch biopsy at baseline and Week 16 from the randomized regions (separate consent).
Exclusion Criteria:
* Hurley III (extensive sinus tracts).
* No qualifying nodule(s) in paired bilateral regions in past 4 weeks.
* Prior device/procedure to target areas within 3 months (chemical peel, dermabrasion, microneedling/RF, other lasers/LBB, cryo/chemo-destruction)
* Had Botulinum toxin in target areas within 3 months or planned during study.
* Had systemic retinoid (e.g., isotretinoin) within 3 months.
* Photosensitizing meds that, in PI's judgment, materially increase risk and cannot be held.
* Pregnancy/breastfeeding/plans to conceive during study.
* Active infection, still healing wounds (investigator judgment) in target areas.
* History of keloids/hypertrophic scars, radiation to target areas, malignancy in target areas, diagnosed immunodeficiency, uncontrolled coagulation disorder or therapeutic anticoagulation that cannot be safely managed.
* Excessive tanning or inability to avoid tanning.
* Any condition (medical/mental) or prisoner status that in PI's opinion compromises safety or adherence.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.